Bio-technology developer Cellmid has secured patent coverage for its Evolis anti-ageing hair care and hair loss products in the potentially large China market.
The Chinese Patent Office has issued notification of its grant of the patent “method of treatment of Alopecia with Monoterpenoids.”
Monoterpenoids are a class of terpenes found in botanical extracts and formulated into the Evolis hair therapy range (pictured) .
The company said in a statement: “Granting of this patent in China is an important commercial milestone for the company’s Chinese product strategy.
“It provides broad protection of (our) technology and several ingredients, adding value to the company’s asset portfolio.”
The company also derives market protection from the Australian Made logo and its registered trademarks.
In 2019 Cellmid beefed up its Chinese marketing with an e-commerce agreement with Aeon International, and plans to have its products registered and sold through Chinese pharmacies and clinics.
Cellmid’s technology is based on the inhibition of a hair growth regulator – fibroblast growth factor 5 (FGF5).
Subscribe to our free @AuManufacturing newsletter here.